Cargando…

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) have completely changed the treatment of cancer, and they also can cause multiple organ immune-related adverse reactions (irAEs). Among them, rheumatic irAE is less common, mainly including inflammatory arthritis, rheumatic myalgia/giant cell arteritis, inflammato...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Yan, Zeng, Lin, Shen, Qinglin, Zhou, Zhiyong, Mao, Zhifang, Wang, Qin, Zhang, Xiquan, Li, Yingliang, Yao, Weirong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424376/
https://www.ncbi.nlm.nih.gov/pubmed/32832568
http://dx.doi.org/10.1155/2020/2640273
_version_ 1783570327170711552
author Xiao, Yan
Zeng, Lin
Shen, Qinglin
Zhou, Zhiyong
Mao, Zhifang
Wang, Qin
Zhang, Xiquan
Li, Yingliang
Yao, Weirong
author_facet Xiao, Yan
Zeng, Lin
Shen, Qinglin
Zhou, Zhiyong
Mao, Zhifang
Wang, Qin
Zhang, Xiquan
Li, Yingliang
Yao, Weirong
author_sort Xiao, Yan
collection PubMed
description Immune checkpoint inhibitors (ICIs) have completely changed the treatment of cancer, and they also can cause multiple organ immune-related adverse reactions (irAEs). Among them, rheumatic irAE is less common, mainly including inflammatory arthritis, rheumatic myalgia/giant cell arteritis, inflammatory myopathy, and Sjogren's syndrome. For oncologists, rheumatism is a relatively new field, and early diagnosis and treatment is very important, and we need to work closely with experienced rheumatologists. In this review, we focused on the incidence, clinical characteristics, and treatment strategies of rheumatic irAE.
format Online
Article
Text
id pubmed-7424376
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-74243762020-08-20 Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors Xiao, Yan Zeng, Lin Shen, Qinglin Zhou, Zhiyong Mao, Zhifang Wang, Qin Zhang, Xiquan Li, Yingliang Yao, Weirong J Immunol Res Review Article Immune checkpoint inhibitors (ICIs) have completely changed the treatment of cancer, and they also can cause multiple organ immune-related adverse reactions (irAEs). Among them, rheumatic irAE is less common, mainly including inflammatory arthritis, rheumatic myalgia/giant cell arteritis, inflammatory myopathy, and Sjogren's syndrome. For oncologists, rheumatism is a relatively new field, and early diagnosis and treatment is very important, and we need to work closely with experienced rheumatologists. In this review, we focused on the incidence, clinical characteristics, and treatment strategies of rheumatic irAE. Hindawi 2020-08-04 /pmc/articles/PMC7424376/ /pubmed/32832568 http://dx.doi.org/10.1155/2020/2640273 Text en Copyright © 2020 Yan Xiao et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Xiao, Yan
Zeng, Lin
Shen, Qinglin
Zhou, Zhiyong
Mao, Zhifang
Wang, Qin
Zhang, Xiquan
Li, Yingliang
Yao, Weirong
Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
title Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
title_full Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
title_fullStr Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
title_full_unstemmed Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
title_short Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors
title_sort diagnosis and treatment of rheumatic adverse events related to immune checkpoint inhibitors
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424376/
https://www.ncbi.nlm.nih.gov/pubmed/32832568
http://dx.doi.org/10.1155/2020/2640273
work_keys_str_mv AT xiaoyan diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors
AT zenglin diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors
AT shenqinglin diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors
AT zhouzhiyong diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors
AT maozhifang diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors
AT wangqin diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors
AT zhangxiquan diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors
AT liyingliang diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors
AT yaoweirong diagnosisandtreatmentofrheumaticadverseeventsrelatedtoimmunecheckpointinhibitors